The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Thomas Bo Jensen, Copenhagen University Hospital, Denmark
  • Dorthe Bartels, Amgros - The Regions’ Pharmaceutical Organisation, Denmark
  • Eva Aggerholm Sædder
  • Birgitte Klindt Poulsen, Aalborg University Hospital, Denmark
  • Stig Ejdrup Andersen, Zealand University Hospital, Denmark
  • Mette Marie H Christensen, University of Southern Denmark, Denmark
  • Lars Nielsen, The Hospital Pharmacy of the Capital Region of Denmark
  • ,
  • Hanne Rolighed Christensen, Copenhagen University Hospital, Denmark
Purpose A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, butmost countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF
inhibitor biosimilars (infliximab and etanercept).
Methods We shed light on the considerations and experiences made during the implementation, and present key figures from the implementation.
Results The infliximab biosimilar constituted 90.6%of the total amount of infliximab fourmonths following patent expiration of the biooriginator. Similar results were seen for etanercept biosimilar. Substantial cost reductions were experienced in the way that e.g. the infliximab-shift reduced cost by two thirds.
Conclusion We believe that a thorough preparation and an organizational setting supporting the implementation is crucial for the successful implementation. This same implementation model will be used for future biosimilars.
Original languageEnglish
JournalEuropean Journal of Clinical Pharmacology
Pages (from-to)35-40
Number of pages6
Publication statusPublished - Jan 2020

    Research areas

  • Biological drugs, Biosimilars, Pharmacoeconomics, Non-medical shift, Anti-TNF drugs

See relations at Aarhus University Citationformats

ID: 170578863